Peculiarities of diagnostics and clinical course of different immunohistochemical subtypes of breast cancer

Modern global guidelines in oncology consider treatment of various forms of breast cancer according to molecular tumor subtype. Steroid receptors, epidermal growth factor receptors, p53, Ki67 proliferative activity index and others are the key indicators of aggressiveness of malignant breast tumors....

Full description

Saved in:
Bibliographic Details
Main Authors: El Khazhzh M.Kh., Bondarenko I.M., Aseyev O.I., Shponka I.S., Zavizion V.F., Sklyar A.S., Vinichenko L.M., Khodzhuzh M.I., Kunik A.V., Artemenko M.V.
Format: Article
Language:English
Published: Dnipro State Medical University 2014-09-01
Series:Medičnì Perspektivi
Subjects:
Online Access:http://medpers.dsma.dp.ua/issues/2014/N3/29-35.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850058973315596288
author El Khazhzh M.Kh.
Bondarenko I.M.
Aseyev O.I.
Shponka I.S.
Zavizion V.F.
Sklyar A.S.
Vinichenko L.M.
Khodzhuzh M.I.
Kunik A.V.
Artemenko M.V.
author_facet El Khazhzh M.Kh.
Bondarenko I.M.
Aseyev O.I.
Shponka I.S.
Zavizion V.F.
Sklyar A.S.
Vinichenko L.M.
Khodzhuzh M.I.
Kunik A.V.
Artemenko M.V.
author_sort El Khazhzh M.Kh.
collection DOAJ
description Modern global guidelines in oncology consider treatment of various forms of breast cancer according to molecular tumor subtype. Steroid receptors, epidermal growth factor receptors, p53, Ki67 proliferative activity index and others are the key indicators of aggressiveness of malignant breast tumors. The material for this study was the retrospective study of the standard set of breast cancer immuno¬histochemical markers (estrogen receptors, progesterone, epidermal growth factor type 2) in 8171 patients. 4 groups of patients - luminal A, luminal B, triple negative and HER2-neu positive subtypes of tumors were identified according to immunohistochemical status. We analyzed overall survival without relapse in 491 patients with breast cancer, clinical data and data of immunohistochemical studies were matched. Based on the investigation it was determined that in the early stages of the disease (1-2) luminal A subtype of cancer is often diagnosed. In the late stages the most common subtype is HER2-neu positive breast cancer. Herewith, patients with luminal A subtype of cancer have the best performance of the overall survival (OS ) (32,91±2,33 months), and the worst results were found in patients with HER2 - neu positive breast cancer (22,58±1,28 months). The data obtained determine HER2 - neu positive subtype as the most aggressive type of breast cancer, and the luminal A subtype – as the least aggressive one.
format Article
id doaj-art-4dda75284d554283b53f0affb03ddbf5
institution DOAJ
issn 2307-0404
2307-0404
language English
publishDate 2014-09-01
publisher Dnipro State Medical University
record_format Article
series Medičnì Perspektivi
spelling doaj-art-4dda75284d554283b53f0affb03ddbf52025-08-20T02:51:00ZengDnipro State Medical UniversityMedičnì Perspektivi2307-04042307-04042014-09-011932935Peculiarities of diagnostics and clinical course of different immunohistochemical subtypes of breast cancerEl Khazhzh M.Kh.0Bondarenko I.M.1Aseyev O.I.2Shponka I.S.3Zavizion V.F.4Sklyar A.S.5Vinichenko L.M.6Khodzhuzh M.I.7Kunik A.V.8Artemenko M.V. 9SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»Modern global guidelines in oncology consider treatment of various forms of breast cancer according to molecular tumor subtype. Steroid receptors, epidermal growth factor receptors, p53, Ki67 proliferative activity index and others are the key indicators of aggressiveness of malignant breast tumors. The material for this study was the retrospective study of the standard set of breast cancer immuno¬histochemical markers (estrogen receptors, progesterone, epidermal growth factor type 2) in 8171 patients. 4 groups of patients - luminal A, luminal B, triple negative and HER2-neu positive subtypes of tumors were identified according to immunohistochemical status. We analyzed overall survival without relapse in 491 patients with breast cancer, clinical data and data of immunohistochemical studies were matched. Based on the investigation it was determined that in the early stages of the disease (1-2) luminal A subtype of cancer is often diagnosed. In the late stages the most common subtype is HER2-neu positive breast cancer. Herewith, patients with luminal A subtype of cancer have the best performance of the overall survival (OS ) (32,91±2,33 months), and the worst results were found in patients with HER2 - neu positive breast cancer (22,58±1,28 months). The data obtained determine HER2 - neu positive subtype as the most aggressive type of breast cancer, and the luminal A subtype – as the least aggressive one.http://medpers.dsma.dp.ua/issues/2014/N3/29-35.pdfbreast cancerimmunohistochemical statusdiagnosticsclinical progressionoverall survival
spellingShingle El Khazhzh M.Kh.
Bondarenko I.M.
Aseyev O.I.
Shponka I.S.
Zavizion V.F.
Sklyar A.S.
Vinichenko L.M.
Khodzhuzh M.I.
Kunik A.V.
Artemenko M.V.
Peculiarities of diagnostics and clinical course of different immunohistochemical subtypes of breast cancer
Medičnì Perspektivi
breast cancer
immunohistochemical status
diagnostics
clinical progression
overall survival
title Peculiarities of diagnostics and clinical course of different immunohistochemical subtypes of breast cancer
title_full Peculiarities of diagnostics and clinical course of different immunohistochemical subtypes of breast cancer
title_fullStr Peculiarities of diagnostics and clinical course of different immunohistochemical subtypes of breast cancer
title_full_unstemmed Peculiarities of diagnostics and clinical course of different immunohistochemical subtypes of breast cancer
title_short Peculiarities of diagnostics and clinical course of different immunohistochemical subtypes of breast cancer
title_sort peculiarities of diagnostics and clinical course of different immunohistochemical subtypes of breast cancer
topic breast cancer
immunohistochemical status
diagnostics
clinical progression
overall survival
url http://medpers.dsma.dp.ua/issues/2014/N3/29-35.pdf
work_keys_str_mv AT elkhazhzhmkh peculiaritiesofdiagnosticsandclinicalcourseofdifferentimmunohistochemicalsubtypesofbreastcancer
AT bondarenkoim peculiaritiesofdiagnosticsandclinicalcourseofdifferentimmunohistochemicalsubtypesofbreastcancer
AT aseyevoi peculiaritiesofdiagnosticsandclinicalcourseofdifferentimmunohistochemicalsubtypesofbreastcancer
AT shponkais peculiaritiesofdiagnosticsandclinicalcourseofdifferentimmunohistochemicalsubtypesofbreastcancer
AT zavizionvf peculiaritiesofdiagnosticsandclinicalcourseofdifferentimmunohistochemicalsubtypesofbreastcancer
AT sklyaras peculiaritiesofdiagnosticsandclinicalcourseofdifferentimmunohistochemicalsubtypesofbreastcancer
AT vinichenkolm peculiaritiesofdiagnosticsandclinicalcourseofdifferentimmunohistochemicalsubtypesofbreastcancer
AT khodzhuzhmi peculiaritiesofdiagnosticsandclinicalcourseofdifferentimmunohistochemicalsubtypesofbreastcancer
AT kunikav peculiaritiesofdiagnosticsandclinicalcourseofdifferentimmunohistochemicalsubtypesofbreastcancer
AT artemenkomv peculiaritiesofdiagnosticsandclinicalcourseofdifferentimmunohistochemicalsubtypesofbreastcancer